New York, NY (PRWEB) March 01, 2012
Parker Waichman LLP, a national law firm representing people injured by defective drugs, has filed lawsuits on behalf of two women who allegedly suffered femur fractures due to their use of Fosamax (Alendronate) for several years. Both Fosamax lawsuits were filed on February 17, 2012 in the Superior Court of New Jersey, Law Division, Atlantic County, where lawsuits involving alleged Fosamax side effects have been designated a mass tort (In re: Fosamax Litigation (No. 282 NJ. Super. Ct.). Both Fosamax lawsuits filed by Parker Waichman LLP name Merck Sharp & Dohme Corp. f/k/a Merck & Co., Watson Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc. as Defendants.
According to her lawsuit, plaintiff Irene Zarra, a resident of the state of Pennsylvania, was prescribed Fosamax and consistently used the drug in a foreseeable manner between September 5, 2004 and February 2010. On February 20, 2010, Ms. Zara suffered a left femur facture (Docket No. L-114-12MT).
A second lawsuit filed on behalf of Lucille Handle of Connecticut alleges she was prescribed and consistently took Fosamax in a foreseeable manner between January 21, 2006 and February 2010. On February 25, 2010, Ms. Handle suffered a right femur fracture. According to her complaint, she later sustained a left femur fracture on November 23, 2010 (Docket No. L-115-12MT).
Both lawsuits allege that, as a direct and proximate result of their long-term use of Fosamax, the Plaintiffs suffered severe mental and physical pain and suffering, and have and will continue to sustain permanent injuries and emotional distress, along with economic losses resulting from medical expenses and living-related expenses related to their new lifestyle.
Both plaintiffs allege they would never have used Fosamax had the Defendants properly disclosed the risks associated with its long-term use. Both lawsuits seek compensatory, punitive and treble damages, as well as ascertainable economic losses, reimbursement of the cost of Fosamax, reimbursement for all past, present and future health and medical costs related to Fosamax per quod, and derivative damages on behalf of the plaintiffs.
“These women are just two examples of the hundreds of women that have suffered unnecessary femur fractures because they used a product that has no proven long-term efficacy,” states Matthew McCauley, who is the leading attorney in the Bisphosphonate Litigation Group at Parker Waichman LLP investigating Fosamax, Actonel and Boniva related femur fracture. "We look forward to the start of the first trials in this litigation, tentatively scheduled for the fall."
Fosamax is an oral bisphosphonate, a class of drugs approved to treat bone disorders, including osteoporosis in post-menopausal women, and Paget's disease. Other oral bisphosphonates include the drugs Actonel, Boniva, Didronel and Skelid. Another class of bisphosphonates that are administered intravenously, including Aredia, Bonefos, and Zometa, are used to prevent fractures due to bone metastases in cancer patients. In October 2011, the U.S. Food & Drug Administration asked the manufacturers of bisphosphonates used to treat osteoporosis, including Fosamax, to add information to the "Warnings and Precautions" section of the drugs’ labels describing the risk of atypical thigh fractures after a study linked long-term use of such drugs to this side effect.
Parker Waichman LLP continues to offer free legal consultations to victims of Fosamax side effects. If you or a loved experienced an atypical femur fracture and you believe Fosamax is to blame, please contact their office by visiting the firm’s Fosamax side effects page at http://www.yourlawyer.com. Free case evaluations are also available by calling 1-800-LAW-INFO (1-800-529-4636).
For more information regarding Fosamax side effects lawsuits and Parker Waichman LLP, please visit: http://www.yourlawyer.com or call 1-800-LAW-INFO (1-800-529-4636).
Parker Waichman LLP
Herbert Waichman, Partner